Dimethylheptyl homolog of cannabidiol in dogs
Cannabidiol (CBD) is one of the major non-psychoactive cannabinoids produced by Cannabis sativa L. Recent studies have shown that a dimethylheptyl homolog (DMH) of cannabidiol is more active as an anticonvulsant than is the naturally occurring cannabidiol. As a potential antiepileptic agent, its pharmacokinetics was studied in dogs (N = 8) after both intravenous (20 milligram) and oral (80 milligram) administration.
Related: Get our guide to CBD
After intravenous administration, the average terminal half-life was 2 hours and its plasma levels decline in a biphasic fashion, with a total body clearance of 8.3 liters/hour. With normalization, this clearance value was less than one half of the value of the hepatic blood flow. In four of the eight dogs studied, dimehtylheptyl homolog could not be detected in the blood plasma after oral administration.
In the other four, the oral bio-availability were all less than fifty percent. After oral administration, dimethylheptyl homolog has a low and variable bio-availability, due to a liver first-pass effect and incomplete absorption from the gastrointestinal tract.
In comparison with cannabidiol, dimethylheptyl homolog has a shorter half-life and lower clearance and volume of distribution values, and its liver extraction ratio is about one half that of cannabidiol.
Read full article by clicking on the link below:
